Efficacy News and Research

RSS

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

17 Oct 2013

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

Mutations in a gene that codes for the enzyme BRAF kinase have been associated with increased risk for papillary thyroid cancer. An early-stage clinical trial of the BRAF inhibitor vemurafenib resulted in either a partial response or stable disease in patients with PTC and BRAF mutations.

17 Oct 2013

Imaxio Sells Genomics Division To Hybrigenics

...

16 Oct 2013

Jain Foundation Steps Up Efforts To Find Cure For Muscular Dystrophy

...

16 Oct 2013

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

ESTEVE, a pharmaceutical company focused on developing novel therapeutics for pain today announces positive top line results from its recently completed phase II trial, which was designed to evaluate the efficacy and safety of E-58425 in acute pain.

16 Oct 2013

Results of Phase 3 clinical trial of contraceptive vaginal ring presented by Population Council

Today, the Population Council presented findings from a Phase 3 clinical trial that was designed to demonstrate the safety, efficacy, and acceptability of the Council's investigational one-year contraceptive vaginal ring (CVR).

16 Oct 2013

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint.

16 Oct 2013

Study illuminates definitive brain alterations in troops with Gulf War Illness

New research illuminates definitive brain alterations in troops with Gulf War Illness thought to result from the exposure to neurotoxic chemicals, including sarin gas, during the first Persian Gulf War.

15 Oct 2013

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

House dust mite allergy is a surprisingly prevalent problem. Something like 27% of the U.S. population and 20% of the European population are what’s called skin-prick test positive for house dust mites, which is a test for sensitivity to allergens to find out if a person is likely to get that allergy.

15 Oct 2013

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience, Inc., a leading global drug discovery and development service company, today announces that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

From Xstrahl 15 Oct 2013

Viewpoints: Marketplaces' 'technical foibles' may keep young people from coming back; health law may be ushering in era of narrow networks

The encouraging view is that the overwhelming number of visitors to the site indicates high demand for insurance in the new system. That's critical, because the more people who participate, the better the system works. The danger is that the technical foibles since Oct. 1 will discourage people from coming back, particularly the young and healthy customers the system needs to keep rates reasonable. With some big deadlines approaching, the Obama administration needs to fix the bugs, and fast. People who need insurance from the federal marketplace have until mid-December to buy coverage that begins Jan. 1. If enrollment figures aren't robust by then, the new health-care system will have a problem even bigger than a frustrating Web (10/11).

15 Oct 2013

Weight Watchers community-based approach more effective than DIY approach

A new randomized controlled trial conducted by Baylor College of Medicine researchers and published today as an Article in Press in The American Journal of Medicine finds that overweight and obese adults following a community-based weight loss intervention, namely Weight Watchers, lost significantly more weight than those who tried to lose weight on their own (10.1 lbs. vs. 1.3 lbs. at six months).

15 Oct 2013

Study: Non-hallucinogenic components of cannabis may act as effective anti-cancer agents

The anti-cancer properties of tetrahydrocannabinol (THC), the primary hallucinogenic component of cannabis, has been recognised for many years, but research into similar cannabis-derived compounds, known as cannabinoids, has been limited.

15 Oct 2013

High doses of ADHD drugs may be effective for people with amphetamine dependency

People with ADHD and dependency rarely respond as they should to ADHD drugs. A randomised study from Karolinska Institutet in Sweden now shows that it is possible to obtain the desired efficacy by administering the drug in higher doses.

15 Oct 2013

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

AstraZeneca (NYSE: AZN) today announced the results of a Phase III long-term safety and tolerability study of the once-daily 25mg dose of naloxegol, in patients with non-cancer pain and opioid-induced constipation (OIC).

15 Oct 2013

Drug treatment ineffective for acute bronchitis

A study published in the BMJ indicates that neither oral antibiotics nor nonsteroidal anti-inflammatory drugs are more effective than placebo for the treatment of acute bronchitis.

14 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Sanofi's Nasacort Allergy 24HR nasal spray receives FDA approval for over-the-counter use

Sanofi announced today that the U.S. Food and Drug Administration approved Nasacort Allergy 24HR nasal spray as an over-the-counter treatment for seasonal and year-round nasal allergies in adults and children 2 years of age and older.

12 Oct 2013

Auxilium Licenses Stendra From Vivus For Up To $300M

...

11 Oct 2013

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.

11 Oct 2013

Efficacy News and Research

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

Imaxio Sells Genomics Division To Hybrigenics

Jain Foundation Steps Up Efforts To Find Cure For Muscular Dystrophy

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

Results of Phase 3 clinical trial of contraceptive vaginal ring presented by Population Council

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Study illuminates definitive brain alterations in troops with Gulf War Illness

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Viewpoints: Marketplaces' 'technical foibles' may keep young people from coming back; health law may be ushering in era of narrow networks

Weight Watchers community-based approach more effective than DIY approach

Study: Non-hallucinogenic components of cannabis may act as effective anti-cancer agents

High doses of ADHD drugs may be effective for people with amphetamine dependency

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

Drug treatment ineffective for acute bronchitis

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Sanofi's Nasacort Allergy 24HR nasal spray receives FDA approval for over-the-counter use

Auxilium Licenses Stendra From Vivus For Up To $300M

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News